Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,343 result(s) found. Displaying page 547 of 2,218.
    «« First « Previous 543  544  545  546  547  548  549  550  551  Next» Last»»
    EudraCT Number: 2014-005119-17 Sponsor Protocol Number: BAY86-5321/17850 Start Date*: 2015-05-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: Open-label Phase-4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept acco...
    Medical condition: Diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    18.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) IT (Completed) LT (Completed) ES (Completed) PT (Completed) FR (Completed) DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003600-40 Sponsor Protocol Number: 218MS305 Start Date*: 2014-09-15
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects w...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed) CZ (Completed) IT (Completed) FI (Completed) BG (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001259-22 Sponsor Protocol Number: 1160.105 Start Date*: 2014-08-05
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: open-label, single dose, tolerability, Pharmacokinetic/Pharmacodynamics and safety study of dabigatran etexilate given at the end of standard anticoagulant therapy in children aged less than 1 yea...
    Medical condition: venous thrombotic event
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) IT (Prematurely Ended) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001524-30 Sponsor Protocol Number: 20140128 Start Date*: 2014-12-11
    Sponsor Name:Amgen Inc.
    Full Title: A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab
    Medical condition: Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) BE (Completed) DE (Completed) IS (Completed) GB (Completed) ES (Prematurely Ended) CZ (Completed) IE (Prematurely Ended) NL (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003298-40 Sponsor Protocol Number: SCALES Start Date*: 2014-12-15
    Sponsor Name:Instituto de Investigación La Fe
    Full Title: STUDY OF THE EFFICACY AND SAFETY MANAGEMENT OF LIRAGLUTIDE IN TYPE 2 DIABETIC PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROME. IMPACT ON CARDIOVASCULAR RISK FACTOR.
    Medical condition: TYPE 2 DIABETIC HOSPITALIZED PATIENTS WITH ACUTE CORONARY SYNDROME.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003547-35 Sponsor Protocol Number: 16160A Start Date*: 2015-04-07
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label, flexible-dose, long-term study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in elderly patients with major depressive disorder with a...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    18.0 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000801-38 Sponsor Protocol Number: KFL3502 Start Date*: 2016-02-19
    Sponsor Name:Mundipharma Research Limited
    Full Title: A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in sub...
    Medical condition: Asthma Bronciale
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003555 Asthma bronchial LLT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004977-34 Sponsor Protocol Number: IgPro20_4005 Start Date*: 2016-02-15
    Sponsor Name:CSL Behring, LLC
    Full Title: Study of immune deficiency patients treated with subcutaneous immunoglobulin (IgPro20, Hizentra®) on weekly and biweekly schedules
    Medical condition: Primary Immune Deficiency Secondary Immune Deficiency
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-003733-25 Sponsor Protocol Number: CHUBX2013/27 Start Date*: 2014-12-03
    Sponsor Name:CHU de BORDEAUX
    Full Title: Pilot Study related to the effect of clopidogrel on plasmatic soluble CD40 ligand during systemic lupus erythematous
    Medical condition: systemic lupus erythematous
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004026-34 Sponsor Protocol Number: SB8-G31-NSCLC Start Date*: 2016-06-27
    Sponsor Name:Samsung Bioepis Co., Ltd.
    Full Title: A Phase III, Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB8 (proposed bevacizumab biosimilar) and Avastin® in Subjects ...
    Medical condition: The intended use of SB8 is the treatment of metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000321-12 Sponsor Protocol Number: 001/2016 Start Date*: 2018-02-08
    Sponsor Name:ÁREA DE ATENCIÓN INTEGRADA DE ALBACETE
    Full Title: Effectiveness in preventing RAdial Spasm of different vasoDIlators and topic Local Anaesthesia during transradial cardiac catheterization: The E-RADIAL trial.
    Medical condition: Radial spasm during cardiac catheterization
    Disease: Version SOC Term Classification Code Term Level
    19.1 10047065 - Vascular disorders 10003175 Arterial spasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003549-90 Sponsor Protocol Number: TBE50 Start Date*: 2014-11-24
    Sponsor Name:Landstinget Sörmland Landstingskansliet, Hälso-och Sjukvårdsledningen
    Full Title: Is it possible to improve humoral response to TBE vaccine in elderly (50+ year olds) by means of changed dosage intervals/number of doses?
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004395-28 Sponsor Protocol Number: MANTRA Start Date*: 2014-12-24
    Sponsor Name:Azienda Ospedaliero-Universitaria di Parma
    Full Title: Phase II randomized study of maintenance regorafenib vs placebo in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metas...
    Medical condition: HER2 negative locally advanced/metastatic gastric or gastroesophagel junction cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001362-10 Sponsor Protocol Number: BAY14-2222/16287 Start Date*: 2014-11-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: Routine prophylaxis treatment versus On-demand treatment for Children with severe Hemophilia A: comparison of all bleeding events in Chinese Hemophilia patients
    Medical condition: Patients with Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10060612 Hemophilia A LLT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-004984-30 Sponsor Protocol Number: AD-4833/TOMM40_303 Start Date*: 2015-03-04
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Co...
    Medical condition: Mild cognitive impairment due to Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10009846 Cognitive impairment LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005106-38 Sponsor Protocol Number: V112_02 Start Date*: 2014-12-04
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Nov...
    Medical condition: Prophylaxis of A (H1N1) 2009 Pandemic Influenza
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002281-70 Sponsor Protocol Number: 2014-002281-70 Start Date*: 2015-02-19
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1?infected patients (<100 CD4+ T cells/?L) taking antiretroviral regimens based on dolutegravir or ritonavir-boosted daru...
    Medical condition: tratement HIV infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004624-21 Sponsor Protocol Number: AC-055-404 Start Date*: 2015-04-13
    Sponsor Name:ACTELION Pharmaceuticals Ltd.
    Full Title: A randomized, double-blind, placebo-controlled, prospective, multicenter, parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension
    Medical condition: Portopulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10067281 Portopulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001221-98 Sponsor Protocol Number: 1.3 Start Date*: 2018-06-25
    Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology
    Full Title: DEXAMETHASONE AS ADJUVANT FOR PERIPHERAL NERVE BLOCKADE: A RANDOMIZED, TRIPLE-BLINDED AND CROSSOVER STUDY IN VOLUNTEERS
    Medical condition: The combination of local anaesthetics plus dexamethasone shall increase the duration of regional anaesthetic blocks. It is a volunteers´study. Three different block combination are performed. One b...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003314-24 Sponsor Protocol Number: CC-10004-PPSO-001 Start Date*: Information not available in EudraCT
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis in adolescents (ages 12 to 17 years, inclusive) and in children (ages 6 to 11 years, inclusive).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 543  544  545  546  547  548  549  550  551  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 00:44:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA